Nuclear factor kappa-light-chain-enhancer of activated B cells subunit 1 (NF-κB p50)

The **p50 subunit of NF-κB** (Nuclear factor kappa-light-chain-enhancer of activated B cells subunit 1) is a DNA-binding subunit of the NF-κB family of transcription factors, which are master regulators of gene transcription involved in inflammation, immunity, cell survival, and cell proliferation[1][5]. The p50 protein is produced by proteolytic processing of the larger p105 precursor (encoded by the NFKB1 gene), during which the C-terminal region is removed via the ubiquitin-proteasome pathway[1]. The mature p50 protein lacks an intrinsic transactivation domain and typically forms dimers: as a homodimer, p50 can repress transcription, while p50/p65 heterodimers are potent transcriptional activators[1][3][4][5]. The p50 subunit binds specific κB DNA sites as part of complexes whose nuclear localization and activity are tightly regulated by inhibitor proteins (IκBs)[5]. Aberrant activation or deregulation of p50-containing NF-κB complexes is implicated in the pathogenesis of many diseases, including cancers, inflammatory and autoimmune conditions, and some infectious diseases[5]. Small molecules, natural products, and designed aptamers that inhibit p50-containing complexes are under investigation as therapeutic agents, but no highly selective p50-targeted drugs are currently approved for clinical use[2][5].

Other names

NF-κB1 p50NF-kappaB p50NFKB1 p50p50 subunitp105 (precursor)NF-κB p50 homodimerNuclear factor NF-kappa-B p50 subunit

Inhibition of DNA binding activity, Inhibition of dimerization, Blocking nuclear translocation, Preventing interaction with co-activators or IκB degradation